Capricor Therapeutics (NASDAQ:CAPR) Issues Quarterly Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.29), FiscalAI reports.

Here are the key takeaways from Capricor Therapeutics’ conference call:

• Capricor said HOPE-3 met its primary endpoint, with a 1.1-point difference on the upper-limb function measure versus placebo (p=0.029). The company also highlighted supportive two-year open-label results and analyses combining HOPE-2 and HOPE-3, while noting the open-label findings are descriptive.
• The FDA review of deramiocel remains ongoing, with a PDUFA date of November 22, 2026. Capricor submitted a major amendment including 24-month HOPE-3 data and additional analyses; its proposed indication focuses on upper-limb impairment in DMD patients older than nine.
• Capricor says its San Diego GMP facility is ready to supply an initial launch if the drug is approved, with further build-out expected to support 2,000–2,500 patients annually at full capacity. The company is preparing launch functions and says it does not expect the NS Pharma dispute to prevent commercialization.
• Third-quarter operating expenses rose to $44.7 million from $26.3 million a year earlier, and net loss widened to $42.7 million; the company reported no revenue. Capricor had $198.5 million in cash, restricted cash and marketable securities and expects funding for at least 12 months, but also reduced its workforce by about 10% and slowed some pipeline work.
• The contractual dispute with Nippon Shinyaku and NS Pharma is proceeding to arbitration, with a hearing expected to begin in mid-2027. Capricor is preparing to commercialize independently and said it is not currently seeking another partner.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded down $0.52 during midday trading on Thursday, reaching $10.70. 1,942,874 shares of the company traded hands, compared to its average volume of 3,187,529. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The business has a 50 day moving average of $8.09 and a two-hundred day moving average of $19.99. The firm has a market capitalization of $621.92 million, a price-to-earnings ratio of -4.06 and a beta of 0.80.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CAPR. Ladenburg Thalmann & Co. Inc. lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Maxim Group lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Piper Sandler upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st. Finally, Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Hold” and an average price target of $29.77.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.